1,001 results on '"Pritchard, Kathleen I"'
Search Results
352. Antihormone Therapy in Recurrent Metastatic Breast Cancer
353. In Reply
354. Utility of metformin in breast cancer treatment, is neoangiogenesis a risk factor?
355. High insulin levels in newly diagnosed breast cancer patients reflect underlying insulin resistance and are associated with components of the insulin resistance syndrome
356. Efficacy, Toxicity, and Quality of Life in Older Women With Early-Stage Breast Cancer Treated With Letrozole or Placebo After 5 Years of Tamoxifen: NCIC CTG Intergroup Trial MA.17
357. Late Extended Adjuvant Treatment With Letrozole Improves Outcome in Women With Early-Stage Breast Cancer Who Complete 5 Years of Tamoxifen
358. Aromatase inhibitors in adjuvant therapy for hormone receptor positive breast cancer: A systematic review
359. HER-2 and Topoisomerase II As Predictors of Response to Chemotherapy
360. Randomized Trial of High-Dose Chemotherapy With Autologous Peripheral-Blood Stem-Cell Support Compared With Standard-Dose Chemotherapy in Women With Metastatic Breast Cancer: NCIC MA.16
361. Combining endocrine agents with chemotherapy: Which patients and what sequence?
362. Endocrine and targeted manipulation of breast cancer: Summary statement for the Sixth Cambridge Conference
363. Do adjuvant aromatase inhibitors increase the cardiovascular risk in postmenopausal women with early breast cancer
364. Lymphedema in women with breast cancer: characteristics of patients screened for a randomized trial
365. Role of Gonadotropin-Releasing Hormone Analog in the Management of Male Metastatic Breast Cancer Is Uncertain
366. Triple-Negative Breast Cancer: Clinical Features and Patterns of Recurrence
367. HER2/neu in systemic therapy for women with breast cancer: a systematic review
368. Risk of chemotherapy induced menopause: More detailed data will lead to improved quality of life
369. Efficacy of Letrozole Extended Adjuvant Therapy According to Estrogen Receptor and Progesterone Receptor Status of the Primary Tumor: National Cancer Institute of Canada Clinical Trials Group MA.17
370. Proposal for Standardized Definitions for Efficacy End Points in Adjuvant Breast Cancer Trials: The STEEP System
371. Tamoxifen-Associated Hot Flashes in Women
372. Randomized, Double-Blind, Placebo-Controlled Trial of Erythropoietin in Non–Small-Cell Lung Cancer With Disease-Related Anemia
373. Adjuvant therapy of the very young woman
374. Effect of Metformin vs Placebo on Weight and Metabolic Factors in NCIC CTG MA.32.
375. Quality of Life Analyses in a Clinical Trial of DPPE (tesmilifene) Plus Doxorubicin Versus Doxorubicin in Patients with Advanced or Metastatic Breast Cancer: NCIC CTG Trial MA.19
376. HER2and Responsiveness of Breast Cancer to Adjuvant Chemotherapy
377. Duration of letrozole treatment and outcomes in the placebo-controlled NCIC CTG MA.17 extended adjuvant therapy trial
378. Proceedings of the Fifth International Conference on Recent Advances and Future Directions in Endocrine Therapy for Breast Cancer: Conference Summary Statement
379. Managing Patients on Endocrine Therapy: Focus on Quality-of-Life Issues
380. Breast Cancer Prevention with Selective Estrogen Receptor Modulators
381. The Early Breast Cancer Trialists Collaborative Group (EBCTCG) Process: Is it Still Relevant in 2006?
382. Cardiovascular Health and Aromatase Inhibitors
383. Adjuvant endocrine therapies for pre-/perimenopausal women
384. Serum Lipids and Outcome of Early-stage Breast Cancer: Results of a Prospective Cohort Study
385. A review of exemestane in the management of breast cancer
386. Estimating per patient funding for cancer clinical trials: An Ontario based survey
387. Prognostic factors affecting the natural history of node-negative breast cancer
388. A Randomized Trial of Letrozole in Postmenopausal Women After Five Years of Tamoxifen Therapy for Early-Stage Breast Cancer
389. A Randomized Trial of Letrozole in Postmenopausal Women after Five Years of Tamoxifen Therapy for Early-Stage Breast Cancer
390. A Comparison of Risk Perception and Psychological Morbidity in Women with Ductal Carcinoma in situ and Early Invasive Breast Cancer
391. Insulin-like growth factor binding proteins 1 and 3 and breast cancer outcomes
392. Hormone Replacement Therapy After Breast Cancer.
393. The Effect of Group Psychosocial Support on Survival in Metastatic Breast Cancer
394. Hormone Replacement in Women with a History of Breast Cancer
395. Changing concepts in hormonal therapy
396. Should Tamoxifen Be Used to Treat Premenopausal Women with Breast Cancer?
397. The fox guarding the clinical trial: internal vs. external validity in randomized studies
398. Adjuvant Treatment and Onset of Menopause Predict Weight Gain After Breast Cancer Diagnosis
399. Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: a population based cohort study
400. Phase I studies of fluorouracil, doxorubicin and vinorelbine without (FAN) and with (SUPERFAN) folinic acid in patients with advanced breast cancer
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.